You are here: Industry Insights > COVID-19

News List

Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19 prnasia
November 04, 2020
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has submitted an Investigational New Drug (IND) application with the ...
New drug candidate for the treatment of COVID-19 worldpharmanews
November 02, 2020
Researchers from the University of Kent, the Goethe-University in Frankfurt am Main (Germany), and the Hannover Medical School (Germany) have identified a drug with the potential to provide a treatment for COVID-19.
Microvascular Dysfunction in COVID-19 Patients: MYSTIC Study prnewswire
November 02, 2020
Research reveals that COVID-19 patients have severe damage to microcirculation and the endothelial glycocalyx. The data in a newly released study clearly show severe reduction of microcirculation and the endothelial glycocalyx in patients with COVID-19 ..
COVID-19 is threatening the UK’s medical research prowess, say charities europeanpharmaceuticalreview
November 02, 2020
UK government warned the financial impact of the COVID-19 pandemic is threatening the future of UK medical research, as 40 percent of early-career scientists look to leave.
Ampio Begins Phase Trial of Inhaled Ampion for COVID-19 Patients with Respiratory Distress americanpharmaceuticalreview
November 02, 2020
Ampio Pharmaceuticals has begun recruiting and enrolling patients in a Phase I multi-center, randomized, controlled trial for a total of 40 patients that will assess the safety and efficacy of inhaled Ampion added to the standard of care (SOC) for ...
Truvian to Make Rapid Antibody Testing More Accessible with Easy Check COVID-19 IgM/IgG? POC Antibody Test americanpharmaceuticalreview
November 02, 2020
Truvian Sciences announced its submission of the Easy Check COVID-19 IgM/IgG? Point-of-Care (POC) Antibody Test to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).
Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination contractpharma
November 02, 2020
cGMP manufacturing of the two long-acting antibodies to begin in H1 2021 at Lonza's Portsmouth, NH (USA) site.
hIVIG is good COVID-19 treatment option but faces competition from convalescent plasma expresspharma
November 02, 2020
Unlike convalescent plasma, hIVIG is a plasma product that is a standardised and concentrated mixture of polyclonal antibodies against the SARS-CoV-2.
India, UK enter into new COVID-19 research partnerships expresspharma
November 02, 2020
A GBP 8-million joint funding initiative will support collaborative research focused on understanding the severity of COVID-19 in South Asian populations in India.
Biocon ranked among top five biotech employers by US-based Science magazine expresspharma
November 02, 2020
Biocon has ranked among the Top 5 Global Biotech Employers for 2020 on the US-based Science magazine’s annual ‘Science Careers Top 20 Employers’ list. Ranked at No. 5 among global pharma and biotech companies in 2020, Biocon has moved up from No. 7 in ...